Bristol-Myers Squibb Company (BMY)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	36,653,000	32,137,000	34,656,000	35,078,000	35,056,000	36,966,000	37,107,000	37,450,000	39,605,000	39,677,000	42,503,000	44,505,000	48,336,000	41,364,000	41,853,000	42,844,000	43,387,000	24,390,000	24,433,000	5,635,000
Total assets	US$ in thousands	95,159,000	91,263,000	93,489,000	94,281,000	96,820,000	98,196,000	100,357,000	103,034,000	109,314,000	110,893,000	110,797,000	112,435,000	118,481,000	125,536,000	128,076,000	129,285,000	129,944,000	57,433,000	55,163,000	34,834,000
Debt-to-assets ratio		0.39	0.35	0.37	0.37	0.36	0.38	0.37	0.36	0.36	0.36	0.38	0.40	0.41	0.33	0.33	0.33	0.33	0.42	0.44	0.16

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $36,653,000K ÷ $95,159,000K
= 0.39

The debt-to-assets ratio for Bristol-Myers Squibb Co. has shown some fluctuations over the past eight quarters. The ratio ranged from 0.40 to 0.44 during this period, with the lowest point being in Q2 2023 and the highest in Q1 2022. Overall, the trend indicates that the company has maintained a relatively stable level of debt relative to its total assets, with the ratio hovering around the 0.40 to 0.44 range. This suggests that Bristol-Myers Squibb Co. has been effectively managing its leverage and maintaining a strong asset base to support its debt obligations.